Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
Canada
Princess Margaret Hospital, Toronto, Ontario Jewish General Hospital, Montreal, Quebec South Korea
Seoul National University Hospital, Seoul Asan Medical Center, Seoul Samsung Medical Center, Seoul The Catholic University of Korea Seoul St Marys Hospital, Seoul Spain
Hosp. Univ. Germans Trias I Pujol, Badalona Hosp Clinic de Barcelona, Barcelona Hosp Univ Fund Jimenez Diaz, Madrid Clinica Univ. de Navarra, Pamplona Hosp Clinico Univ de Salamanca, Salamanca Taiwan
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City China Medical University Hospital, Taichung National Cheng Kung University Hospital, Tainan National Taiwan University Hospital, Taipei